S3
Supporting Information Contents

Experimental S3
Fig. S1. Crystal structure showing the positions tested for 19 F-labelling. S7 Fig. S2 . Mass spectrometric analysis of BTFA labelling of OXA-48 variants S8 Fig. S3 . 19 F-NMR spectra for varying concentrations of OXA-48 T213C* S9 Fig. S4 . 19 F-NMR spectra showing impact of bicarbonate on OXA-48 variants S10 Table S1 . Michaelis-Menten kinetic values for 19 F-labelled OXA-48 variants S11 Fig. S5 . Product profiles of OXA-48 and OXA-48 T213C* with meropenem S12 Fig. S6 . Circular dichroism spectra for 19 F-labelled OXA-48 variants S13 Fig. S7 . Impact of pH on the carbamylation state of 19 F-labelled OXA-48 variants S14 Fig. S8 . 13 C-NMR spectra of 19 F-labelled OXA-48 variants S15 Table S2 . Processing and refinement statistics for OXA-48 T213C* crystallography S23
S4
were combined, concentrated (using 10 kDa molecular-weight cut-off Amicon centrifugal filters;
EMD Millipore), and loaded onto a 300 mL Superdex 200 column (GE Life Sciences) preequilibrated in gel filtration buffer (50 mM HEPES, pH 7.5, 200 mM NaCl). The Superdex column was washed with one column volume of gel filtration buffer, and 5 mL fractions were collected.
Fractions of the desired purity (>95%), as identified by SDS-PAGE, were combined, buffer exchanged into 50 mM sodium phosphate, pH 7.5, concentrated using an Amicon centrifugal filter, frozen in liquid nitrogen, then stored at -80 °C. The identity and purity of the purified protein was confirmed by MS.
For 1-bromo-3,3,3-trifluoroacetone (BTFA) labelling, [2] protein aliquots were thawed on ice; neat BTFA was added to give a final ratio of 15 BTFA : 1 enzyme. The mixture was incubated on ice for 10 minutes, then buffer exchanged into 50 mM sodium phosphate, pH 7.5 using a preequilibrated PD-10 column (GE Healthcare), then dialyzed overnight against 50 mM sodium phosphate, pH 7.5 using a Slide-A-Lyzer Dialysis cassette (10 kDa molecular-weight cut-off filter). The labelled protein was concentrated using an Amicon centrifugal filter, frozen in liquid nitrogen, and stored at -80 °C. Complete labelling (within detection limits) was confirmed by mass spectrometry ( Figure S2 ).
NMR Spectroscopy
1 H, 13 in CDCl 3 as an external standard. A line broadening of 10 Hz was applied to 13 C-and 19 F-NMR spectra.
Mass Spectrometry
Protein mass spectra were acquired using a Waters Micromass LCT Premier XE spectrometer coupled with an Acquity UPLC system. Samples consisted of 1 µM protein prepared in 50 mM sodium phosphate, pH 7.5. Protein signals were deconvoluted using the MaxEnt1 function of MassLynx V4.1 (Waters).
Circular Dichroism
Circular dichroism spectra were acquired at 25 °C using a Chirascan CD spectrometer (Applied Photophysics model). [3] Samples were made up of 0.2 mg/mL enzyme in 10 mM sodium phosphate, pH 7.5, and a 0.1 cm cuvette was used. The data shown represent the smoothed average of three measurements over the range of 185 nm to 260 nm, using 0.5 nm increments. Each point was averaged for 1 s.
Enzyme Kinetics
Enzymatic hydrolysis of nitrocefin and meropenem was monitored using a PHERAstar FS plate reader (BMG Labtech). [3] Hydrolysis experiments were performed at 25 °C with 96-well UV-Star Microplates (Greiner Bio-One), monitoring the change in absorbance at 486 nm for nitrocefin (ε = 20,500 M -1 cm -1 ), or at 295 nm for meropenem (ε = 10,940 M -1 cm -1 ). The buffer used for assays consisted of 100 mM sodium phosphate, pH 7.5, 50 mM sodium bicarbonate with 0.01%
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Triton X-100. For the meropenem degradation assays, enzyme concentrations of 75 nM (OXA-48 wild-type), 2500 nM (OXA-48 L158C*) or 400 nM (OXA-48 T213C*) were used. For the nitrocefin degradation assays, enzyme concentrations of 25 pM (OXA-48 wild-type), 125 pM (OXA-48 L158C*), or 50 pM (OXA-48 T213C*) were used. Non-linear regression analyses were carried out using Prism 5 (GraphPad) to determine kinetic parameters.
X-ray Crystallography
Purified and 19 F-labelled OXA-48 T213C* was buffer exchanged into 50 mM MES, pH 6.0, with 50 mM NaHCO 3 . Crystallisation trials were carried out using the PACT premier broad screen (Molecular Dimensions). A structure of OXA-48 T213C* (PDB 6RJ7) was solved using a crystal obtained from a well solution consisting of 0.2 M CaCl 2 , 0.1 M Tris, pH 8.0, and 20 % w/v PEG 6000. Data were collected at the Diamond Light Source synchrotron IO4-1 beamline at 100 K, were indexed and integrated with XDS, and scaled using SHELX. [4] The structure was solved by molecular replacement using Phaser, [5] using PDB entry 4S2P as a search model. [6] Fitting and refinement were carried out using COOT [7] and PHENIX, [8] until R work and R free no longer converged. The statistics for data collection and refinement are described in Table S2 . Figure S1 . View from a crystal structure of OXA-48 (PDB 3HBR), [9] showing the positions chosen for 19 F-labelling with 1-bromo-3,3,3-trifluoroacetone. The nucleophilic serine, Ser70, and the carbamylated lysine, KCX73, are represented as white sticks; the residues that were substituted with cysteine residues are shown as yellow sticks. , and G161C were ~18 Da greater than calculated. This mass difference suggests that the ketone group in the label is (at least, predominantly) hydrated, as observed crystallographically (Figure 4 ), and consistent with small molecule hydration studies. [10] Table S1 , which differed in terms of the buffer conditions and enzyme concentrations used), these data show that the ratio of lactone and hydrolysis products are similar for both wild-type OXA-48 and OXA-48 T213C*. Note that the lactone and hydrolysis products are present as a mixture of tautomers and diastereomers. [11] Figure S6. Circular dichroism spectra for the 19 F-labelled OXA-48 variants. The spectra acquired for the 19 F-labelled OXA-48 L158C* and T213C* variants resemble that of wild-type OXA-48. Based on these spectra (and as supported by the kinetic data shown in Table S1 and the crystallographic studies shown in Figure 4 ), the amino acid substitutions and 19 F-labelling do not appear to significantly impact on the overall folds of the OXA-48 variants, as compared to the wild-type enzyme. In the absence of bicarbonate, the peak corresponding to carbamylated OXA-48 L158C* could not be clearly observed, while a clear peak was present in the corresponding spectrum of OXA-48 T213C*. Based on these NMR spectra, it appeared that carbamylation is relatively disfavoured with the OXA-48 L158C* variant, as compared to the T213C* variant. Figure 1C , S1); residues of the β5 and β6 strands are shown with a blue background. The high level of sequence variation in the β5-β6 loop between different enzymes suggests this is an appropriate position for the 19 F-label. The nucleophilic serine and carbamylated lysine residues are shown with yellow backgrounds. Sequence alignment was performed using Clustal Omega (https://www.ebi.ac.uk/Tools/msa/clustalo/), and the β-lactamases sequences were retrieved from the Beta-Lactamase DataBase (BLDB). [13] As the temperature of the sample was increased, the extent of carbamylation was observed to decrease (i.e., peak 3 decreased in intensity). (C) Proposed structures corresponding to the 19 F signals observed for OXA-48 T213C* with relebactam and zidebactam. These assignments are based in part on those shown in Figure S10 . The R groups correspond to the structures of relebactam and zidebactam shown in Figure S10 . Figure S8 , and as described previously); [12] those in orange are assigned as corresponding to the complex of vaborbactam covalently bound to carbamylated OXA-48 T213C* (resembling what was observed previously for the carbamylated complex of a cyclic boronate with OXA-10). [14] The spectra acquired suggest that OXA-48 T213C* is not fully complexed with vaborbactam (due to the apparent presence of two peaks, and the relatively weak signal intensities), consistent with the relatively poor binding interaction shown in Figure S15 . However, we cannot exclude the possibility that the binding of vaborbactam may impact the dynamics of OXA-48 T213C*, thereby impacting signal intensity and broadness. 
